In a bid to gain access to a costly AIDS drug sold by ViiV Healthcare, Kazakhstan officials may go to court and pursue a compulsory license, the latest dispute in which a cash-strapped government is considering sidestepping patents in order to provide medicines to its citizens.

At issue is a blockbuster treatment called dolutegravir that is sold under the Tivicay brand name by the company, which is actually a venture largely controlled by GlaxoSmithKline (GSK), although Pfizer (PFE) and Shionogi have small stakes. ViiV was formed a decade ago to concentrate on developing HIV and AIDS drugs, which have regularly been a flashpoint in the global debate over access to medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • And so it would seem, holiday weekend or not, the ‘gate to the Pharmalot’ is always open. Interesting development, mr ed, with more to come, I’m sure.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy